FDA Approves Amgen’s EVENITY™ for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture

Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced that the U.S. Food and Drug Administration (FDA) has approved EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY is the first and only bone builder with a unique dual effect that both increases bone formation and to a lesser extent reduces bone resorption (or bone loss) to rapidly reduce the risk of fracture. A full course of EVENITY therapy is 12 monthly doses administered by a healthcare provider.2 Since osteoporosis is a chronic disease, continued therapy with an anti-resorptive agent should be considered once EVENITY therapy is completed.

Click here to read the complete interactive Multichannel News Release… 

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more